At the 92nd Annual Congress of the European Atherosclerosis Society (26-29 May 2024, Lyon, France, and online), Lp(a) presentations included recent data which demonstrated a causal link between Lp(a) and chronic kidney disease and underlined the importance of elevated Lp(a) in contributing to the risk of heterozygous familial hypercholesterolaemia. These topical presentations also encouraged the […]
Observational and genetic data from the Copenhagen General Population Study have supported a causal link between Lp(a) and chronic kidney disease (CKD), with an increased risk comparable with that seen for Lp(a) and myocardial infarction and aortic valve stenosis.
Adding elevated Lp(a) concentration to traditional risk factors significantly enhances CV risk estimation in patients with heterozygous familial hypercholesterolaemia (HeFH), according to results of a study in 147 patients clinically diagnosed with HeFH.
LDL-C and ApoB measurements do not adequately capture risk of atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis (AVS). This is the conclusion from an analysis of data from 70,189 individuals in the Copenhagen General Population Study, 7,127 of whom developed ASCVD and 1,516 developed AVS during a median 10.8 years of follow up.
Targeting the LPA gene via specific microRNAs (miRs) that control its expression appears a promising option for lowering Lp(a), in the light of data presented at the congress. Professor Gilles Lambert and Romuald Techer (University of La Réunion Medical School, Reunion Islands) reported results of research to investigate the ability of four miRs (miR-455-5p, miR-22-5p, […]
